Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTT: Tailoring Obesity Treatment Trial
2024-510802-10-00Phase 3Withdrawn
- Sponsor
- Hospital of South West Jutland
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of semaglutide and pramlintide in obesity and prediabetes, sponsored by Hospital of South West Jutland. Primary endpoint: Change in kilocalorie consumption at ad libitum meal test. Planned start Dec 2024; status: withdrawn.
02
Drugs
semaglutidepramlintide
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on 2024-510802-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510802-10-00.